MicroRNA-503 acts as a tumor suppressor in glioblastoma for multiple antitumor effects by targeting IGF-1R

Zhang, Yingying; Xiong, Chen; Lian, Haiwei; Liu, Jian‐Miao; Zhou, Beiyan; Han, Song; Peng, Biwen; Yin, Jun; Liu, Wanhong; He, Xiaohua

doi:10.3892/or.2013.2951

Cited by 38 publications

(38 citation statements)

References 40 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MicroRNA-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin D1 [19]. miR-503 acts as a tumor suppressor in glioblastoma for multiple antitumor effects by targeting IGF-1R [17]. Recently, miR-503 was reported to be downregulated in HCC and involve HCC progression [20].…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

miR-503 suppresses metastasis of hepatocellular carcinoma cell by targeting PRMT1

Liu

et al. 2015

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 97%

“…It has been reported that miR-503 is downregulated in several tumor types including non-small cell lung cancer [14], oral cancer [15], gastric cancer [16], glioblastoma [17]. In these tumors miR-503 functions as tumor suppressor by repressing oncogene expression.…”

Section: Introductionmentioning

confidence: 99%

miR-503 suppresses metastasis of hepatocellular carcinoma cell by targeting PRMT1

Liu

et al. 2015

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

“…The overexpression of PYK2 was associated with activation of the PI3K/AKT pathway and poor survival and metastasis in hepatocellular carcinoma [37]. Additionally, as miR-503 targets and inhibits PI3K/AKT activation [40,41], the suppression of miR-503 in recipient cells may result in the up regulation of PI3K/AKT signaling and the subsequent promotion of metastasis.…”

Section: Microparticles Mediate the Enhancement Of Metastatic Traitsmentioning

confidence: 99%

Microparticles in cancer: A review of recent developments and the potential for clinical application

Gong

Jaiswal

Dalla

et al. 2015

Seminars in Cell & Developmental Biology

View full text Add to dashboard Cite

Once thought of as inert remnants of cellular processes, the significance of membrane vesicles is now expanding as their capacity to package and transfer bioactive molecules during intercellular communication is established. This ability to serve as vectors in the trafficking of cellular cargo is of mounting interest in the context of cancer, particularly in the dissemination of deleterious cancer traits from parent cells to recipient cells. Although microparticles (MPs) contribute to the pathogenesis of cancer, their unique characteristics can also be also exploited in the context of cancer treatment. The detection of MPs in body fluids has the potential to provide an effective means for the diagnosis, prognosis and surveillance of cancer patients. The use of such easily accessible systemic biomarkers that reflect the characteristics of the parent cells circumvents the need for invasive biopsy procedures. In addition, the autologous nature of MPs may allow them to be used as novel therapeutic drug carriers. Thus the modulation of MP vesiculation, the detection of MPs in disease monitoring, and the application of MPs as therapeutic delivery vehicles present prospective clinical interventions in the treatment of cancer. Revision Notes1. The authors overviewed the contribution of microparticles (MPs) to the pathogenesis of cancer and the potential for clinical application of MPs. In contrast to the title of the manuscript "Microparticles in Cancer: A Review of Recent Developments and the Potential for Clinical Application.", a large part of the content of this manuscript occupied the refer and discussed on the publications of the authors' group. The authors should discuss more generally on state-of-the-art for clinical application of MPs or some other extracellular vesicles (EVs). The authors have now included an extra section on Page 10 discussing the clinical applications of extracellular vesicles in cancer.2. The authors should refer to sufficient publications in general, especially in cancer-derived extracellular vesicles.Other references relevant to this study have now been added.3. The term "microparticles" mainly used in this manuscript is not well documented. Is there any specific differences between MPs and EVs? If so please describe those appropriately in the text. An explanation has now been added on Page 3 to describe the different membrane vesicles.4. The authors described "exosomes" in the text in the section 4. However, there is no mentioned the differ from MPs. This is a very confusing. An explanation of the different membrane vesicles has now been included on Page 3.5. The content of the figure is a very limited information. Modify the figure more generously including more other findings on tumor metastasis and drug resistance. Additional figures have now been included. Revision NotesAbbreviations: Matrix metalloproteinases, MMPs; mesenchymal stem cells, MSC; MPs, microparticles; miRNA, microRNA; microvesicles, MVs; MDR, multidrug resistance; non-small cell lung carcinoma, NSCLC; P-gp, P...

show abstract

“…One pathway by which miR-503 acts as a tumor suppressor is via downregulation of phosphatidylinositol 3-kinase (PI3K)/AKT signaling (17). The PI3K/AKT signaling pathway plays an important role in the progression of breast cancer (18, 19).…”

Section: Introductionmentioning

confidence: 99%

Microparticles Mediate the Intercellular Regulation of microRNA-503 and Proline-Rich Tyrosine Kinase 2 to Alter the Migration and Invasion Capacity of Breast Cancer Cells

et al. 2014

View full text Add to dashboard Cite

The successful treatment of cancer is hampered by drug resistance and metastasis. While these two obstacles were once considered separately, recent evidence associates resistance with an enhanced metastatic capacity. However, the underlying mechanisms remain undefined. We previously described the intercellular transfer of drug resistance via submicron vesicles called microparticles (MPs). We now propose that MPs derived from drug-resistant cells are also involved in the intercellular transfer of components to enhance the migration and invasion capacity of cells. Thus, MPs may be a conduit between resistance and metastasis. We used microarray analysis to identify regulatory microRNAs (miRNAs), which contribute to the dissemination of metastatic traits. miR-503 was downregulated in recipient cells following co-culture with MPs isolated from drug-resistant cells. miR-503 was inversely associated with metastasis, as demonstrated using wound healing/scratch migration assays and Matrigel®-coated transwell invasion assays. Proline-rich tyrosine kinase 2 (PYK2) was upregulated in recipient cells and associated with increased migration and invasion, with these phenotypes being reversed using a pharmacological inhibitor of PYK2 phosphorylation, tyrphostin A9. However, the MP-mediated promotion of metastatic traits was not due to the presence of these effectors in the MP cargo but rather due to down stream effector molecules in these pathways. This is the first demonstration that the role of MPs in trait acquisition extends beyond the direct transfer of vesicle components and also includes transfer of intermediary regulators that induce down stream mediators following transfer to recipient cells. This implicates an expanding role of MPs in cancer pathogenesis.

show abstract

MicroRNA-503 acts as a tumor suppressor in glioblastoma for multiple antitumor effects by targeting IGF-1R

Cited by 38 publications

References 40 publications

miR-503 suppresses metastasis of hepatocellular carcinoma cell by targeting PRMT1

miR-503 suppresses metastasis of hepatocellular carcinoma cell by targeting PRMT1

Microparticles in cancer: A review of recent developments and the potential for clinical application

Microparticles Mediate the Intercellular Regulation of microRNA-503 and Proline-Rich Tyrosine Kinase 2 to Alter the Migration and Invasion Capacity of Breast Cancer Cells

Contact Info

Product

Resources

About